SCHEMBL138263

SCHEMBL138263

COC(=O)c1cc(Br)nc2c1[nH]c1cc(OC)ccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.57
ALDH1A1 P00352 3/20 0.49
HPGD P15428 2/20 0.49
ALOX15 P16050 2/20 0.49
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 2/20 0.49
GAA P10253 2/20 0.49
USP2 O75604 1/20 0.49
MAPT P10636 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
DYRK1A Q13627 6/20 0.46
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
LMNA P02545 1/20 0.45
NR4A2 P43354 1/20 0.45
CDK4 P11802 2/20 0.45
CCND1 P24385 2/20 0.45
CLK1 P49759 2/20 0.44
CDK5 Q00535 2/20 0.44
CDK5R1 Q15078 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL145786 0.87 JAK2 (0.43) JAK2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL145169 0.86 NR4A2 (0.51) JAK2HPGDKDM4ELMNANR4A2
SCHEMBL141121 0.86 JAK2 (0.42) JAK2ALDH1A1HPGDALOX15HSD17B10
SCHEMBL145515 0.84 MAOA (0.49) JAK2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL137418 0.84 JAK2 (0.41) JAK2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL141522 0.84 JAK2 (0.80) JAK2ALDH1A1HPGDALOX15HSD17B10
SCHEMBL145348 0.82 PRMT5 (0.42) JAK2ALDH1A1GAAMAPTLMNA
SCHEMBL142806 0.81 DYRK1A (0.44) JAK2ALDH1A1KDM4EUSP2MAPT
SCHEMBL145708 0.79 JAK2 (0.51) JAK2ALDH1A1HPGDALOX15HSD17B10
SCHEMBL141841 0.79 ALDH1A1 (0.40) JAK2ALDH1A1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885ALDH1A1 1464/4885HPGD 1953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.